Teva halts tests of its migraine drug as a cluster headache remedy

April 23, 2019

Teva Pharmaceutical will now stop developing migraine drug Ajovy (fremanezumab) as a treatment for cluster headaches. This comes after the drugmaker realized it was not likely to meet the goal of a late-stage trial.

The drug was approved as a prevention for migraines in September. It is still being as a treatment for post-traumatic headache.

Ajovy is competing with treatments from Eli Lilly and Amgen, which includes a treatment from the former that received breakthrough status from the U.S. Food and Drug Administration.

Read the Reuters report.